News Otsuka, Vera stake their claims to IgAN treatment Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?
News Otsuka eyes early filing of IgAN drug after phase 3 readout Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.
News UK government reveals neighbourhood healthcare delivery plan The UK government's Neighbourhood Health Service is central to the NHS 10 Year Plan - but can it deliver real change?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face